Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5095 - Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC).

Date

11 Sep 2017

Session

Poster display session

Presenters

Ithar Gataa

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

I. Gataa1, L. Mezquita1, E. Auclin1, S. Le Moulec2, P. Alemany3, M. Kossai3, J. Massé4, C. CARAMELLA5, J. Remon Masip1, J. Lahmar1, R. Ferrara1, A. Gazzah1, J. Soria6, D. Planchard1, B. Besse1, J. Adam3

Author affiliations

  • 1 Medical Oncology Department, Gustave Roussy, 94800 - VILLEJUIF/FR
  • 2 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 3 Pathology Department, Gustave Roussy, 94800 - VILLEJUIF/FR
  • 4 Pathology, Bergonié, 33 - Bordeaux/FR
  • 5 Radiology, Gustave Roussy, 94800 - Villejuif/FR
  • 6 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Abstract 5095

Background

Assessment of tumor infiltrating lymphocytes (TIL) by pathologists using Hematoxylin-Eosin (H&E), has been described as a prognostic factor in resected NSCLC. We aimed to correlate TIL to the benefit from nivolumab in patients (pts) with treated advanced NSCLC.

Methods

Patients with advanced NSCLC treated with nivolumab, with biopsy available for evaluation, were included between November 2012 and February 2017 in two cancer centers. Patients characteristics and outcome were collected. The percentage of tumor infiltrating lymphocytes in the stroma was evaluated using H&E staining from archival pretreatment tumor tissue samples. Primary endpoint was to correlate TIL density with progression free survival (PFS).

Results

Out of ninety-eight patients included. 60 (61%) pts were male, with median age of 61 years and 85 (89%) were smokers. Sixty three (73%) pts were PS 0-1. Sixty tumors (61%) were adenocarcinoma, 29 (30%) squamous and 9 (10%) other histologies. Among 83 tumors with known molecular profile, 22 (27%) were KRAS mutated 7 (8%) EGFR mutated, 1(1%) ALK positive. The median treatment line was 3 (2-4). The median follow up was 8 months (m)(95%CI[6-19]). The median PFS was 2 m (95%CI[1-5]). The ORR was for 16%. The median TIL density was 5% (2-15). TIL density ≥5% correlated with PFS in univariate and multivariate analysis (HR: 0.48 [0.28-0.82] p = 0.007 and HR:0.31 [0.14-0.68] p = 0.004 respectively). TIL density ≥5% was also associated with better ORR (OR = 3.5, 95%CI [1.06-11.7], p = 0.04).

Conclusions

Pathological assessment of TIL allows an easy evaluation of immune infiltration in NSCLC and independently correlates PFS in NSCLC pts treated with nivolumab. Results from validation cohorts and combination with other morphological and immunohistochemical parameters will be reported.

Clinical trial identification

Legal entity responsible for the study

Ithar Gataa

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.